Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
CC transcript
|
|
IDENIX PHARMACEUTICALS INC (IDIX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/31/2014 |
8-K
| Quarterly results|
Docs:
|
"IDENIX PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTH 2014 FINANCIAL RESULTS CAMBRIDGE, Mass., July 31, 2014 — Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter ended June 30, 2014. Second Quarter and Six Months 2014 Financial Results For the second quarter ended June 30, 2014, Idenix reported total revenues of $ million, compared to total revenues of $0.1 million in the second quarter of 2013. The Company reported a net loss of $64.5 million, or $0.43 per basic and diluted share, for the second quarter ended June 30, 2014, compared to a net loss of $28.9 million, or $0.22 per basic and diluted share, for the second qu..." |
|
| 05/01/2014 |
8-K
| Quarterly results|
Docs:
|
"IDENIX PHARMACEUTICALS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS AND HCV PIPELINE REVIEW CAMBRIDGE, Mass., May 1, 2014 — Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the first quarter ended March 31, 2014. HCV Pipeline Review • In April 2014, Idenix reported positive seven-day proof-of-concept data from a phase I/II clinical trial for IDX21437, the Company's lead uridine-based nucleotide prodrug candidate. The trial demonstrated that IDX21437 was well tolerated and exhibited potent pan-genotypic activity with mean maximal viral load reductions of 4.2 - 4.3 log 10 IU/mL for treatment-naïve genotype 1, 2 and 3 HCV-infected patients ..." |
|
| 10/30/2013 |
8-K
| Quarterly results |
| 08/07/2013 |
8-K
| Quarterly results |
| 11/01/2012 |
8-K
| Quarterly results |
| 05/02/2012 |
8-K
| Quarterly results |
| 11/02/2011 |
8-K
| Form 8-K - Current report |
| 08/08/2011 |
8-K
| Form 8-K - Current report |
| 04/27/2011 |
8-K
| Quarterly results|
Docs:
|
"IDENIX PHARMACEUTICALS REPORTS FIRST QUARTER 2011 FINANCIAL RESULTS Cambridge, Mass., — April 27, 2011 - Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the first quarter of 2011. At March 31, 2011, Idenix's cash and cash equivalents totaled $31.4 million. First Quarter 2011 Financial Results For the first quarter ended March 31, 2011, Idenix reported total revenues of $4.0 million, compared to total revenues of $2.7 million in the first quarter of 2010. The company reported a net loss of $8.2 million, or a loss of $0.11 per basic and diluted share, for the first quarter ended March 31, 2011, compared to a net loss of $16.2 million, or a los..." |
|
| 10/29/2010 |
8-K
| Quarterly results |
| 07/26/2010 |
8-K
| Quarterly results |
| 05/03/2010 |
8-K
| Quarterly results |
| 10/29/2009 |
8-K
| Quarterly results |
| 07/20/2009 |
8-K
| Quarterly results |
| 05/01/2009 |
8-K
| Form 8-K -- Current report |
| 10/30/2008 |
8-K
| Quarterly results |
| 07/29/2008 |
8-K
| Quarterly results|
Docs:
|
"IDENIX PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTH FINANCIAL RESULTS Cambridge, MA, July 29, 2008 — Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the second quarter ended June 30, 2008. At June 30, 2008, Idenix's cash, cash equivalents and marketable securities totaled $80.6 million. 2008 Year-to-Date Business Highlights" |
|
| 04/29/2008 |
8-K
| Quarterly results|
Docs:
|
"IDENIX PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS Cambridge, MA, April 29, 2008 — Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the first quarter ended March 31, 2008. At March 31, 2008, Idenix's cash, cash equivalents and marketable securities totaled approximately $99.0 million. 2008 Year-to-Date Business Highlights • Idenix reported positive data from an ongoing phase I/II study of IDX899, a non-nucleoside reverse transcriptase inhibitor being developed for the treatment of HIV-1. In the first dosing cohort of this study, eight HIV-1 infected treatment-naïve patients receiving 800 mg of IDX899 once..." |
|
| 08/07/2007 |
8-K
| Quarterly results|
Docs:
|
"IDENIX PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTH FINANCIAL RESULTS Cambridge, MA, August 2, 2007 - Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the second quarter ended June 30, 2007. At June 30, 2007, Idenix's cash, cash equivalents and marketable securities totaled approximately $160 million with no debt. For the second quarter ended June 30, 2007, Idenix reported total revenues of $19.7 million, compared with total revenues of $19.3 million in the second quarter of 2006. Total revenues for the second quarter of 2007 consist of reimbursement by Novartis Pharma AG of expenses incurred by..." |
|
| 04/26/2007 |
8-K
| Quarterly results|
Docs:
|
"IDENIX PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS Cambridge, MA, April 26, 2007 — Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the first quarter ended March 31, 2007. At March 31, 2007, Idenix's cash, cash equivalents and marketable securities totaled $161.9 million. For the first quarter ended March 31, 2007, Idenix reported total revenues of $24.8 million, compared with total revenues of $13.1 million in the first quarter of 2006. Total revenues for the first quarter of 2007 consist of reimbursement by Novartis Pharma AG of expenses incurred by Idenix in connection with the developmen..." |
|
| 05/02/2006 |
8-K
| Quarterly results |
| 03/02/2006 |
8-K
| Quarterly results |
| 11/03/2005 |
8-K
| Quarterly results |
| 07/28/2005 |
8-K
| Quarterly results |
| 04/28/2005 |
8-K
| Quarterly results|
Docs:
|
"IDENIX PHARMACEUTICALS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS Cambridge, MA; April 28, 2005 - Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the first quarter ended March 31, 2005. For the first quarter ended March 31, 2005, Idenix reported total revenues of $14.9 million, compared with total revenues of $16.7 million in the first quarter of 2004. Total revenues include reimbursement by Novartis of expenses incurred by Idenix in connection with the development of telbivudine and valtorcitabine, Idenix's drug candidates for the treatment of hepatitis B, and amortization of the up-front fees paid to ..." |
|
| 02/24/2005 |
8-K
| Quarterly results |
| 11/02/2004 |
8-K
| Quarterly results|
Docs:
|
"IDENIX PHARMACEUTICALS ANNOUNCES THIRD QUARTER AND NINE MONTH FINANCIAL RESULTS Cambridge, MA; November 02, 2004 - Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported financial results for the third quarter and nine months ended September 30, 2004. For the third quarter ended September 30, 2004, Idenix reported total revenues of $17.2 million, compared with total revenues of $12.7 million in the third quarter of 2003. Total revenues include reimbursements by Novartis Pharma AG of the expenses incurred by Idenix in connection with the development of telbivudine and valtorcitabine, Idenix's drug candidates for the treatment of hepatitis B, and amortization o..." |
|
| 08/26/2004 |
8-K
| Quarterly results|
Docs:
|
"IDENIX PHARMACEUTICALS ANNOUNCES SECOND QUARTER RESULTS Cambridge, MA; August 26, 2004 - Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported financial results for the second quarter and six months ended June 30, 2004. For the second quarter ended June 30, 2004, Idenix reported total revenues of $42.8 million, compared with total revenues of $2.9 million in the second quarter of 2003. Total revenues include reimbursements by Novartis of the expenses incurred by Idenix in connection with the development of telbivudine and valtorcitabine, Idenix's drug candidates for the treatment of hepatitis B, amortization of the up-front fee received when Novartis license..." |
|
|
|